Healios KK (JP:4593) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Healios K.K. has announced its decision to apply for conditional and time-limited approval in Japan for its MultiStem® therapy for acute respiratory distress syndrome (ARDS), based on positive Phase 2 trial results. The company plans to launch a global Phase 3 trial in the U.S. and has cancelled a previously planned Phase 3 trial in Japan. Healios has stated that this development will not affect its consolidated financial results for the fiscal year ending December 31, 2024.
For further insights into JP:4593 stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue